Immunovant Stock Operating Margin
| IMVT Stock | USD 16.08 0.54 3.25% |
Immunovant's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Immunovant Stock price.
Immunovant | Build AI portfolio with Immunovant Stock |
Immunovant Company Operating Margin Analysis
Immunovant's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Immunovant has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Immunovant Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.Immunovant is currently under evaluation in operating margin category among its peers.
Immunovant Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 2.13 B | ||||
| Shares Outstanding | 171.07 M | ||||
| Shares Owned By Insiders | 58.16 % | ||||
| Shares Owned By Institutions | 55.69 % | ||||
| Number Of Shares Shorted | 20.57 M | ||||
| Price To Book | 4.02 X | ||||
| EBITDA | (437.78 M) | ||||
| Net Income | (413.84 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 98 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 4.16 X | ||||
| Cash Flow From Operations | (375.87 M) | ||||
| Short Ratio | 16.06 X | ||||
| Earnings Per Share | (2.73) X | ||||
| Target Price | 41.64 | ||||
| Number Of Employees | 362 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 2.84 B | ||||
| Total Asset | 776.22 M | ||||
| Retained Earnings | (1.24 B) | ||||
| Working Capital | 698.89 M | ||||
| Net Asset | 776.22 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.